🇺🇸 FDA
Pipeline program

PREVYMIS 240 mg film-coated tablets, Placebo of prevymis 240 mg tablets (letermovir), VALGANCICLOVIR

APHP220791

Phase 3 small_molecule active

Quick answer

PREVYMIS 240 mg film-coated tablets, Placebo of prevymis 240 mg tablets (letermovir), VALGANCICLOVIR for CytoMegaloVirus infections, Kidney transplant is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
CytoMegaloVirus infections, Kidney transplant
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials